(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Pneumonia, Lipid D011017 2 associated lipids
Steatorrhea D045602 2 associated lipids
Persian Gulf Syndrome D018923 1 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Ikematsu H et al. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. 2012 Hum Vaccin Immunother pmid:22854661
Vesikari T et al. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. 2012 Hum Vaccin Immunother pmid:22777094
Bencharitiwong R et al. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. 2012 Hum Vaccin Immunother pmid:22777093
Niehaus TD et al. Functional identification of triterpene methyltransferases from Botryococcus braunii race B. 2012 J. Biol. Chem. pmid:22241476
Iorio AM et al. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. 2012 Vaccine pmid:22245606
Ambrose CS and Belshe RB Influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22276839
Heikkinen T and Heinonen S Influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22276840
Gasparini R et al. Aflunov(®): a prepandemic influenza vaccine. 2012 Expert Rev Vaccines pmid:22309663
Spanova M et al. Influence of squalene on lipid particle/droplet and membrane organization in the yeast Saccharomyces cerevisiae. 2012 Biochim. Biophys. Acta pmid:22342273
Palma P et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. 2012 Biologicals pmid:22261282
Heikkinen T et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. 2012 Am. J. Obstet. Gynecol. pmid:22939717
Mannino S et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. 2012 Am. J. Epidemiol. pmid:22940713
Klucker MF et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. 2012 J Pharm Sci pmid:22941944
Vishnubhatla S et al. Contact lenses and the rate of evaporation measured in vitro; the influence of wear, squalene and wax. 2012 Cont Lens Anterior Eye pmid:22906863
Guzmán Herrador BR et al. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. 2012 BMC Infect. Dis. pmid:22429643
Hatz C et al. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. 2012 Vaccine pmid:22446638
Lai RP et al. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 2012 PLoS ONE pmid:22509385
Marinaro M et al. A caprine herpesvirus 1 vaccine adjuvanted with MF59â„¢ protects against vaginal infection and interferes with the establishment of latency in goats. 2012 PLoS ONE pmid:22511971
Cosco D et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. 2012 Int J Nanomedicine pmid:22679366
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Lokvam J and Fine PV An oxidized squalene derivative from Protium subserratum Engl. (Engl.) growing in Peru. 2012 Molecules pmid:22706374
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Granados-Principal S et al. Squalene ameliorates atherosclerotic lesions through the reduction of CD36 scavenger receptor expression in macrophages. 2012 Mol Nutr Food Res pmid:22648620
Song JY et al. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. 2012 Clin. Vaccine Immunol. pmid:22379067
Peric M et al. Electron paramagnetic resonance line shifts and line shape changes due to heisenberg spin exchange and dipole-dipole interactions of nitroxide free radicals in liquids 8. Further experimental and theoretical efforts to separate the effects of the two interactions. 2012 J Phys Chem A pmid:22288424
Takami T et al. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. 2012 PLoS ONE pmid:23145048
Langley JM et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. 2012 BMC Infect. Dis. pmid:23110320
Bihari I et al. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. 2012 Clin. Vaccine Immunol. pmid:23081815
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Liu YT et al. Protein engineering of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase into parkeol synthase. 2012 Org. Lett. pmid:23043506
Ta MT et al. Accumulation of squalene is associated with the clustering of lipid droplets. 2012 FEBS J. pmid:23013491
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498
Binks BP et al. How membrane permeation is affected by donor delivery solvent. 2012 Phys Chem Chem Phys pmid:23073464
Dorea JG Safety of thimerosal in vaccines: for whom and how many doses? 2011 Mar-Apr Therapie pmid:23189333
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Lopez P et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. 2011 J. Infect. Dis. pmid:21606530
Cen-Pacheco F et al. Cytotoxic oxasqualenoids from the red alga Laurencia viridis. 2011 Eur J Med Chem pmid:21616566
Raouane M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. 2011 J. Med. Chem. pmid:21561161
Gill S et al. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. 2011 Cell Metab. pmid:21356516
Kaya K et al. Thraustochytrid Aurantiochytrium sp. 18W-13a accummulates high amounts of squalene. 2011 Biosci. Biotechnol. Biochem. pmid:22056449
Wu J et al. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. 2011 Arch. Virol. pmid:21110049
Packwood DM and Phillips LF A stochastic, local mode study of neon-liquid surface collision dynamics. 2011 Phys Chem Chem Phys pmid:21042647
Andrews N et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. 2011 J. Infect. Dis. pmid:21148494
Kajaste-Rudnitski A et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. 2011 AIDS pmid:21150561
O'Hagan DT et al. MF59 adjuvant: the best insurance against influenza strain diversity. 2011 Expert Rev Vaccines pmid:21506643
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. 2011 Hum Vaccin pmid:21508673
Ačimovič J et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. 2011 Biochem. Biophys. Res. Commun. pmid:21531203
Siedenburg G and Jendrossek D Squalene-hopene cyclases. 2011 Appl. Environ. Microbiol. pmid:21531832